Vaccibody As Stock Debt To Equity

VACCDelisted Stock  USD 2.23  0.04  1.83%   
Vaccibody As fundamentals help investors to digest information that contributes to Vaccibody's financial success or failures. It also enables traders to predict the movement of Vaccibody Stock. The fundamental analysis module provides a way to measure Vaccibody's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Vaccibody stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Vaccibody As Company Debt To Equity Analysis

Vaccibody's Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.

D/E

 = 

Total Debt

Total Equity

More About Debt To Equity | All Equity Analysis

Current Vaccibody Debt To Equity

    
  0.03 %  
Most of Vaccibody's fundamental indicators, such as Debt To Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Vaccibody As is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
Competition

According to the company disclosure, Vaccibody As has a Debt To Equity of 0.033%. This is 99.94% lower than that of the Biotechnology sector and 99.83% lower than that of the Health Care industry. The debt to equity for all Norway stocks is 99.93% higher than that of the company.

Vaccibody Debt To Equity Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Vaccibody's direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Vaccibody could also be used in its relative valuation, which is a method of valuing Vaccibody by comparing valuation metrics of similar companies.
Vaccibody is currently under evaluation in debt to equity category among its peers.

Vaccibody Fundamentals

About Vaccibody Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Vaccibody As's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Vaccibody using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Vaccibody As based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.

Other Consideration for investing in Vaccibody Stock

If you are still planning to invest in Vaccibody As check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Vaccibody's history and understand the potential risks before investing.
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance